

### Hybrigenics first half 2015 revenues and cash

- **Stable turnover at EUR 1.9 million**
- **Doubling of cash position to EUR 14.8 million**

**Paris, 27 July 2015** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in proteomic and genomic scientific services, today announces its revenues and cash position for the first half of 2015.

<b>Million EUR</b>	<b>1<sup>st</sup> Half 2014</b>	<b>1<sup>st</sup> Half 2015</b>
<b>Turnover from scientific services</b>	<b>1.5</b>	<b>1.5</b>
Turnover from research collaboration	0.4	0.4
<b>Total turnover</b>	<b>1.9</b>	<b>1.9</b>
Other operating revenues <sup>a</sup>	0.5	0.4
<b>Total revenues</b>	<b>2.4</b>	<b>2.3</b>
<b>Cash position (end of period)</b>	<b>7.4</b>	<b>14.8</b>

<sup>a</sup> mainly research subsidies, subleases and services to subleasers

Hybrigenics' turnover both from scientific services and from the drug discovery collaboration with Servier on de-ubiquitinating enzymes and their inhibitors have remained stable (EUR 1.5 million and EUR 0.375 million, respectively). Other operating revenues from non-core activities decreased by EUR 0.1 million.

The first half of 2015 is the first semester with only residual turnover (EUR 0.15 million) from the two Hybrigenics Services' biggest historical clients, after the expiration of multiannual contracts with an American life science company for an average of USD 0.75 million per year over the past six years (accordingly to the contracts, cf. Hybrigenics press releases of September 1<sup>st</sup>, 2009 and September 24<sup>th</sup>, 2012), and with L'Oréal for an average of EUR 0.35 million per year over the past 11 years (cf. press releases of December 14<sup>th</sup>, 2007 and September 14<sup>th</sup>, 2010). New and more numerous clients across Europe and in the United States have compensated for the natural end of these two successful long-term collaborations.

Hybrigenics' cash position on June 30<sup>th</sup>, 2015 amounted to EUR 14.8 million, exactly twice as much as on June 30<sup>th</sup>, 2014, and 54% more than the EUR 9.6 million on December 31<sup>st</sup>, 2014, thanks to a successful capital raise of EUR 9 million completed during the first half of 2015 (cf. Hybrigenics' press release of April 7<sup>th</sup>, 2015).

*"Our rapidly growing client base for scientific services in Europe and the US has compensated for two long-term contracts that came to an end. Hybrigenics thus has a renewed and more diversified client base and has demonstrated its ability to transform its technology leadership into a wider geographical reach,"* said Remi Delansorne, Hybrigenics' CEO, who added: *"our cash position is the strongest in 10 years and will allow Hybrigenics to undertake the clinical Phase II study of inecalcitol in acute myeloid patients both in France and in the United States, a therapeutic indication for which inecalcitol has already been designated as an orphan drug in Europe."*

# HYBRIGENICS

## Press Release

### About Hybrigenics

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes (DUBs) and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. A first milestone has been achieved in a drug discovery program targeting one DUB in oncology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



#### **Hybrigenics**

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

#### **NewCap**

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)